Different Icariin doses led to reduced β-catenin and phosphorylated NF-κB p65 protein expression, suggesting the potential of Icariin to control subcutaneously transplanted PC tumor growth and mobility via Wnt/β-catenin and NF-κB pathway inhibition. The gene discussed is NFKB1; the disease is neoplasm.